Author:
Krupp Joanna,Hung Frances,LaChapelle Tina,Yarrington Michael E.,Link Katherine,Choi Yujung,Chen Hillary,Marais Andrea Des,Sachdeva Nidhi,Chakraborty Hrishikesh,McKellar Mehri S.
Publisher
Southern Medical Association
Reference39 articles.
1. Centers for Disease Control and Prevention. U.S. overdose deaths in 2021 increased half as much as in 2020—but are still up 15%. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm. Updated May 11, 2022. Accessed June 26, 2022.
2. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study;Ann Intern Med
3. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population;J Subst Abuse Treat
4. Policy pathways to address provider workforce barriers to buprenorphine treatment;Am J Prev Med
5. Grimm CA. Geographic disparities affect access to buprenorphine services for opioid use disorder. https://oig.hhs.gov/oei/reports/oei-12-17-00240.asp. Published January 29, 2020. Accessed January 20, 2023.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献